Memorial Sloan Kettering Cancer Center clinical trial pipeline

62 trials changed in the last 30 days: 1 stopped, 43 with notable changes, 18 with minor changes only.

1. Stopped

   Trastuzumab Deruxtecan · Non-Small Cell Lung Cancer

   Trial status changed: Recruiting → Withdrawn

   Memorial Sloan Kettering Cancer Center·Phase 2· NCT07428044· Registry history of NCT07428044 on ClinicalTrials.gov (opens the registry)

   Oct 20, 2026

2. Notable

   IMPROVE · Integrative Medicine at Home (IM@HOME) Program…IMPROVE · Integrative Medicine at Home (IM@HOME) Program · Cancer

   Primary and study completion pushed from Sep 20, 2026 to Sep 20, 2027

   Memorial Sloan Kettering Cancer Center·Not applicable· NCT05053230· Registry history of NCT05053230 on ClinicalTrials.gov (opens the registry)

   Oct 20, 2026

3. Notable

   BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial…BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

   Primary and study completion pushed from Sep 2026 to Sep 2027

   Memorial Sloan Kettering Cancer Center·Phase 2· NCT04106414· Registry history of NCT04106414 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

4. Notable

   Tablet-based Mobile Health Ultrasound for Point-of-care Breast…Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)

   Primary completion pushed from Sep 21, 2026 to Sep 21, 2027

   Memorial Sloan Kettering Cancer Center·Not specified· NCT05561842· Registry history of NCT05561842 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

5. Notable

   Captisol Enabled Melphalan and Pharmacokinetics · Multiple Myeloma…Captisol Enabled Melphalan and Pharmacokinetics · Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant

   Primary and study completion pushed from Sep 2026 to Sep 2027

   Memorial Sloan Kettering Cancer Center·Phase 1· NCT02909036· Registry history of NCT02909036 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

6. Notable

   Magnetic Resonance (MR) Imaging to Determine High Risk Areas…Magnetic Resonance (MR) Imaging to Determine High Risk Areas · Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors

   Primary and study completion pushed from Sep 2026 to Sep 2027

   Memorial Sloan Kettering Cancer Center·Not applicable· NCT00870129· Registry history of NCT00870129 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

7. Notable

   Monitoring for Cancer Spread to the Central Nervous System (CNS)…Monitoring for Cancer Spread to the Central Nervous System (CNS) · Breast Cancer

   Primary and study completion pushed from Jul 2026 to Jul 2027

   Memorial Sloan Kettering Cancer Center·Not applicable· NCT05130840· Registry history of NCT05130840 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

8. Notable

   Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor…Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer

   Primary and study completion pushed from Sep 2026 to Sep 2027

   Memorial Sloan Kettering Cancer Center·Not applicable· NCT03289195· Registry history of NCT03289195 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

9. Notable

   Cognitive Health in Survivors of Prostate Cancer

   Primary and study completion pushed from Sep 8, 2026 to Sep 8, 2027

   Memorial Sloan Kettering Cancer Center·Not specified· NCT05540782· Registry history of NCT05540782 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

10. Notable

    Radiation Therapy in Combination With Durvalumab · Pancreatic…Radiation Therapy in Combination With Durvalumab · Pancreatic Cancer

    Primary and study completion pushed from Sep 2026 to Sep 2027

    Memorial Sloan Kettering Cancer Center·Phase 1/2· NCT03245541· Registry history of NCT03245541 on ClinicalTrials.gov (opens the registry)

    Oct 9, 2026

11. Notable

    Imaging, Blood, and Tissue Samples to Guide Treatment of Colon…Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors

    Primary and study completion pushed from Nov 2026 to Nov 2028

    Also in this update: Enrollment reopened; Enrollment increased: 51 → 80 participants

    Memorial Sloan Kettering Cancer Center·Not specified· NCT03432806· Registry history of NCT03432806 on ClinicalTrials.gov (opens the registry)

    Oct 13, 2026

12. Notable

    Partial Breast Irradiation (PBI) Using 40 Gy for Select · Early…Partial Breast Irradiation (PBI) Using 40 Gy for Select · Early Invasive or Noninvasive Breast Cancer

    Primary and study completion pushed from Sep 2026 to Sep 2027

    Memorial Sloan Kettering Cancer Center·Phase 2· NCT01203839· Registry history of NCT01203839 on ClinicalTrials.gov (opens the registry)

    Oct 7, 2026

13. Notable

    Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in…Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve · Progressive Metastatic Castration-resistant Prostate Cancer

    Primary and study completion pushed from Sep 2026 to Sep 2027

    Memorial Sloan Kettering Cancer Center·Phase 1/2· NCT01688492· Registry history of NCT01688492 on ClinicalTrials.gov (opens the registry)

    Oct 6, 2026

14. Notable

    Acupuncture Study for Prostate Cancer Survivors With Urinary Issues

    Primary and study completion pushed from Sep 2026 to Sep 2027

    Memorial Sloan Kettering Cancer Center·Phase 1/2· NCT05540392· Registry history of NCT05540392 on ClinicalTrials.gov (opens the registry)

    Oct 5, 2026

15. Notable

    Adding Precisely Targeted Radiation Therapy (Stereotactic Body…Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) · Breast Cancer

    Primary and study completion pushed from Sep 6, 2026 to Sep 6, 2027

    Memorial Sloan Kettering Cancer Center·Phase 2· NCT05534438· Registry history of NCT05534438 on ClinicalTrials.gov (opens the registry)

    Oct 2, 2026

16. Notable

    ICARuS · Post-operative Intraperitoneal Chemotherapy (EPIC) and…ICARuS · Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis

    Primary and study completion pushed from Sep 2026 to Sep 2027

    Memorial Sloan Kettering Cancer Center·Phase 2· NCT01815359· Registry history of NCT01815359 on ClinicalTrials.gov (opens the registry)

    Oct 2, 2026

17. Notable

    Lenalidomide Maintenance in Plasma Cell Myeloma

    Primary and study completion pushed from Aug 2026 to Aug 2027

    Memorial Sloan Kettering Cancer Center·Phase 2· NCT02538198· Registry history of NCT02538198 on ClinicalTrials.gov (opens the registry)

    Sep 25, 2026

18. Notable

    3-Day Partial Breast Radiation Therapy · Breast Cancer

    Primary and study completion pushed from Aug 30, 2026 to Aug 30, 2027

    Memorial Sloan Kettering Cancer Center·Phase 2· NCT04084730· Registry history of NCT04084730 on ClinicalTrials.gov (opens the registry)

    Sep 21, 2026

19. Notable

    Nivolumab In Combination With Cabozantinib · Non-Clear Cell Renal…Nivolumab In Combination With Cabozantinib · Non-Clear Cell Renal Cell Carcinoma

    Primary and study completion pushed from Aug 2026 to Aug 2027

    Memorial Sloan Kettering Cancer Center·Phase 2· NCT03635892· Registry history of NCT03635892 on ClinicalTrials.gov (opens the registry)

    Sep 21, 2026

20. Notable

    CD371-YSNVZIL-18 CAR T Cells · Acute Myeloid Leukemia

    Primary and study completion pushed from Dec 17, 2026 to Dec 17, 2027

    Memorial Sloan Kettering Cancer Center·Phase 1· NCT06017258· Registry history of NCT06017258 on ClinicalTrials.gov (opens the registry)

    Oct 6, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.